Omeros Corporation (OMER) News

Form 8-K - Current report

Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Primary statistical analysis of overall survival compared TA-TMA patients treated with narsoplimab in its pivotal trial to a cohort of over 100...

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

-- Clinical Trial and Clinical Pharmacology Data Support Upcoming Enrollment of Omeros’ Zaltenibart Phase 3 Clinical Program in PNH -- Omeros...

Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting

-- Presentations Highlight Progress in Late-Stage Development of Lead MASP-3 Inhibitor Zaltenibart -- Omeros Corporation (Nasdaq: OMER) today...

Omeros Corporation Provides Update on Progress Toward BLA Resubmission

Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Omeros Corporation Reports Third Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial...

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on...

FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

-- Phase 3 Studies on the Horizon in both PNH and C3G -- Omeros Corporation today announced that zaltenibart (OMS906) has received rare...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Omeros Corporation Reports Second Quarter 2024 Financial Results

– Conference Call Today at 4:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering...

Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2024, on...

Form 8-K - Current report